香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Ganzhou Hemay Pharmaceutical Co., Ltd. 贛州和美藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向贛州和美藥業股份有限公司（「本公司」）、其獨家保薦人、整體協 調人、顧問或承銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處長 登記的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯 ...

Market Overview - The Hong Kong stock market showed a soft trend, with the Hang Seng Index (HSI) maintaining fluctuations and overall market sentiment being cautious [1] - The pharmaceutical sector exhibited mixed performance, with Kangfang Biopharma (09926) being a notable focus, closing at 140.1 HKD, down 1.68% for the day, with a trading volume of 29.57 billion HKD [1] Company Insights - Kangfang Biopharma's core product, AK112, is expected to release follow-up clinical data at the end of the month during an international medical conference, which has garnered market attention regarding its potential in cancer treatment [1] - The stock has experienced significant short-term volatility, with a 5-day price fluctuation of 21.6% [1] Technical Analysis - Technical indicators suggest a "buy" signal with a strength of 10, while multiple moving averages indicate a "strong buy" signal [3] - The Relative Strength Index (RSI) is at a relatively low level of 35, with several oscillators showing neutral signals, but some indicators indicate oversold conditions, suggesting a potential bottoming phase with a 57% probability of price increase [3] Support and Resistance Levels - The first support level for Kangfang Biopharma is at 128.3 HKD, with a second support level at 109.6 HKD [5] - The first resistance level is at 155.9 HKD, and if this level is surpassed, the second resistance level at 170.6 HKD may be challenged [5] - The current stock price of 140.1 HKD is positioned between the support and first resistance levels, making stability and movement towards the resistance level crucial for future trends [5] Investment Products - For investors optimistic about a rebound, the Huatai call warrant (18380) is recommended, offering a leverage of 3 times with an exercise price of 158.98 HKD, noted for its low premium and implied volatility [5][6] - The Bank of China call warrant (18157) is also worth considering, with a lower leverage of 2.6 times and a similar exercise price, but it has the highest implied volatility among similar products [6] - In terms of bull certificates, UBS's bull certificate (53839) has a high leverage of 4.6 times with a redemption price of 120 HKD, while JPMorgan's bull certificate (55333) offers an even higher leverage of 5.2 times with a redemption price of 124 HKD, suitable for investors confident in a short-term rebound [7][8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加科思藥業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1167） 自願公告 加科思在2024年第66屆美國血液學年會上展示了 BET抑制劑JAB-8263治療骨髓纖維化的初步臨床數據 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統 稱「本集團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發 展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司在加利福尼亞州聖地牙哥 舉行的2024年第66屆美國血液學會（「ASH」）年會上展示了BET抑制劑JAB-8263 治療骨髓纖維化(MF)臨床一期的初步數據。 資料顯示，JAB-8263具有良好的耐受性，二期推薦劑量為0.3毫克（每日給藥）。 JAB-8263單藥治療骨髓纖維化適應症的初步療效資料是令人鼓舞的。大多數 ...